http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 25 Feb 2026 16:16:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vyome+Holdings%2C+Inc+++++++For%3A+Feb+20/26060234.html si-local-file:///var/storage/secattach/20260225/26060234.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vyome+Holdings%2C+Inc+++++++For%3A+Feb+20/26060234.html Wed, 25 Feb 2026 16:16:00 -0500 HIND O.01228167 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vyome+Holdings%2C+Inc+++++++For%3A+Feb+20/26060234.html si-local-file:///var/storage/secattach/20260225/26060234.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vyome+Holdings%2C+Inc+++++++For%3A+Feb+20/26060234.html Wed, 25 Feb 2026 16:16:00 -0500 HIND O.01228167 http://www.streetinsider.com/Press+Releases/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html <p class="bwalignc"> <i>Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Livechain, Inc. (“Livechain”) (OTCX: LICH)</b>, a subsidiary of <b>Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND),</b> announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, <i>d/b/a, </i>Humanyze (“Humanyze”), a rapidly emerging human resources data and analytics company. </p><p> The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued http://www.streetinsider.com/Press+Releases/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html Tue, 24 Feb 2026 08:00:00 -0500 HIND LICH O.01228167 O.48641147 http://www.streetinsider.com/Press+Releases/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html <p class="bwalignc"> <i>Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Livechain, Inc. (“Livechain”) (OTCX: LICH)</b>, a subsidiary of <b>Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND),</b> announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, <i>d/b/a, </i>Humanyze (“Humanyze”), a rapidly emerging human resources data and analytics company. </p><p> The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued http://www.streetinsider.com/Press+Releases/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html Tue, 24 Feb 2026 08:00:00 -0500 HIND LICH O.01228167 O.48641147 http://www.streetinsider.com/Press+Releases/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html <p class="bwalignc"> <i>Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Livechain, Inc. (“Livechain”) (OTCX: LICH)</b>, a subsidiary of <b>Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND),</b> announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, <i>d/b/a, </i>Humanyze (“Humanyze”), a rapidly emerging human resources data and analytics company. </p><p> The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued http://www.streetinsider.com/Press+Releases/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html Tue, 24 Feb 2026 08:00:00 -0500 HIND LICH O.01228167 O.48641147 http://www.streetinsider.com/Press+Releases/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html <p class="bwalignc"> <i>Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Livechain, Inc. (“Livechain”) (OTCX: LICH)</b>, a subsidiary of <b>Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND),</b> announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, <i>d/b/a, </i>Humanyze (“Humanyze”), a rapidly emerging human resources data and analytics company. </p><p> The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued http://www.streetinsider.com/Press+Releases/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html Tue, 24 Feb 2026 08:00:00 -0500 HIND LICH O.01228167 O.48641147 http://www.streetinsider.com/Business+Wire/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html <p class="bwalignc"> <i>Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Livechain, Inc. (“Livechain”) (OTCX: LICH)</b>, a subsidiary of <b>Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND),</b> announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, <i>d/b/a, </i>Humanyze (“Humanyze”), a rapidly emerging human resources data and analytics company. </p><p> The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued http://www.streetinsider.com/Business+Wire/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html Tue, 24 Feb 2026 08:00:00 -0500 HIND LICH O.01228167 O.48641147 http://www.streetinsider.com/Business+Wire/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html <p class="bwalignc"> <i>Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Livechain, Inc. (“Livechain”) (OTCX: LICH)</b>, a subsidiary of <b>Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND),</b> announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, <i>d/b/a, </i>Humanyze (“Humanyze”), a rapidly emerging human resources data and analytics company. </p><p> The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued http://www.streetinsider.com/Business+Wire/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html Tue, 24 Feb 2026 08:00:00 -0500 HIND LICH O.01228167 O.48641147 http://www.streetinsider.com/Business+Wire/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html <p class="bwalignc"> <i>Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Livechain, Inc. (“Livechain”) (OTCX: LICH)</b>, a subsidiary of <b>Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND),</b> announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, <i>d/b/a, </i>Humanyze (“Humanyze”), a rapidly emerging human resources data and analytics company. </p><p> The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued http://www.streetinsider.com/Business+Wire/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html Tue, 24 Feb 2026 08:00:00 -0500 HIND LICH O.01228167 O.48641147 http://www.streetinsider.com/Business+Wire/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html <p class="bwalignc"> <i>Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Livechain, Inc. (“Livechain”) (OTCX: LICH)</b>, a subsidiary of <b>Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND),</b> announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, <i>d/b/a, </i>Humanyze (“Humanyze”), a rapidly emerging human resources data and analytics company. </p><p> The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued http://www.streetinsider.com/Business+Wire/Livechain+Completes+Acquisition+of+Senior%2C+Secured+Debt+of+Humanyze%2C+An+MIT+Incubated%2C+AI+Enabled+HR+Analytics+Company/26047027.html Tue, 24 Feb 2026 08:00:00 -0500 HIND LICH O.01228167 O.48641147 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vyome+Holdings%2C+Inc+++++++For%3A+Feb+13/25994933.html si-local-file:///var/storage/secattach/20260213/25994933.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vyome+Holdings%2C+Inc+++++++For%3A+Feb+13/25994933.html Fri, 13 Feb 2026 06:05:00 -0500 HIND O.01228167 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vyome+Holdings%2C+Inc+++++++For%3A+Feb+13/25994933.html si-local-file:///var/storage/secattach/20260213/25994933.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vyome+Holdings%2C+Inc+++++++For%3A+Feb+13/25994933.html Fri, 13 Feb 2026 06:05:00 -0500 HIND O.01228167 http://www.streetinsider.com/Corporate+News/Vyome+files+for+orphan+drug+status+for+VT-1953+cancer+treatment/25979175.html <p>Vyome Holdings Inc. (NASDAQ: HIND) filed for orphan drug designation with the FDA for VT-1953, its treatment for malignant fungating wounds in advanced cancer patients.</p><p>The Cambridge, Massachusetts-based biopharmaceutical company said orphan drug status would provide seven years of U.S. market exclusivity, up to 25% tax credits on clinical trials conducted in the United States, and exemption from FDA Prescription Drug User Fee Act fees worth approximately $3 million.</p><p>VT-1953 targets malignant fungating wounds, a condition affecting approximately 10% of advanced cancer patients. No FDA-approved therapies currently exist for this condition, which causes severe malodor, pain, and emotional distress in patients.</p><p>The company http://www.streetinsider.com/Corporate+News/Vyome+files+for+orphan+drug+status+for+VT-1953+cancer+treatment/25979175.html Wed, 11 Feb 2026 07:01:00 -0500 HIND http://www.streetinsider.com/FDA/Vyome+files+for+orphan+drug+status+for+VT-1953+cancer+treatment/25979175.html <p>Vyome Holdings Inc. (NASDAQ: HIND) filed for orphan drug designation with the FDA for VT-1953, its treatment for malignant fungating wounds in advanced cancer patients.</p><p>The Cambridge, Massachusetts-based biopharmaceutical company said orphan drug status would provide seven years of U.S. market exclusivity, up to 25% tax credits on clinical trials conducted in the United States, and exemption from FDA Prescription Drug User Fee Act fees worth approximately $3 million.</p><p>VT-1953 targets malignant fungating wounds, a condition affecting approximately 10% of advanced cancer patients. No FDA-approved therapies currently exist for this condition, which causes severe malodor, pain, and emotional distress in patients.</p><p>The company http://www.streetinsider.com/FDA/Vyome+files+for+orphan+drug+status+for+VT-1953+cancer+treatment/25979175.html Wed, 11 Feb 2026 07:01:00 -0500 HIND http://www.streetinsider.com/Press+Releases/Vyome+Files+for+VT-1953+Orphan+Drug+Status%2C+Furthers+Strategic+Focus+On+VT-1953+Program+Over+the+Next+6+Months/25979130.html <ul class="bwlistdisc"> <li> <i>Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&amp;D tax benefits, and PDUFA fee waiver of approximately $3M</i> </li> <li> <i>Independent third-party assessment estimates a current VT-1953 valuation of approximately $455M today and ~$1B after a successful Phase 3 study</i> </li> <li> <i>FDA interactions planned in Q2 2026 for the Phase 3 protocol based on earlier announced positive Phase 2 results</i> </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc. (“<b>Vyome</b>”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical http://www.streetinsider.com/Press+Releases/Vyome+Files+for+VT-1953+Orphan+Drug+Status%2C+Furthers+Strategic+Focus+On+VT-1953+Program+Over+the+Next+6+Months/25979130.html Wed, 11 Feb 2026 07:00:00 -0500 HIND O.01228167 http://www.streetinsider.com/Press+Releases/Vyome+Files+for+VT-1953+Orphan+Drug+Status%2C+Furthers+Strategic+Focus+On+VT-1953+Program+Over+the+Next+6+Months/25979130.html <ul class="bwlistdisc"> <li> <i>Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&amp;D tax benefits, and PDUFA fee waiver of approximately $3M</i> </li> <li> <i>Independent third-party assessment estimates a current VT-1953 valuation of approximately $455M today and ~$1B after a successful Phase 3 study</i> </li> <li> <i>FDA interactions planned in Q2 2026 for the Phase 3 protocol based on earlier announced positive Phase 2 results</i> </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc. (“<b>Vyome</b>”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical http://www.streetinsider.com/Press+Releases/Vyome+Files+for+VT-1953+Orphan+Drug+Status%2C+Furthers+Strategic+Focus+On+VT-1953+Program+Over+the+Next+6+Months/25979130.html Wed, 11 Feb 2026 07:00:00 -0500 HIND O.01228167 http://www.streetinsider.com/Business+Wire/Vyome+Files+for+VT-1953+Orphan+Drug+Status%2C+Furthers+Strategic+Focus+On+VT-1953+Program+Over+the+Next+6+Months/25979130.html <ul class="bwlistdisc"> <li> <i>Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&amp;D tax benefits, and PDUFA fee waiver of approximately $3M</i> </li> <li> <i>Independent third-party assessment estimates a current VT-1953 valuation of approximately $455M today and ~$1B after a successful Phase 3 study</i> </li> <li> <i>FDA interactions planned in Q2 2026 for the Phase 3 protocol based on earlier announced positive Phase 2 results</i> </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc. (“<b>Vyome</b>”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical http://www.streetinsider.com/Business+Wire/Vyome+Files+for+VT-1953+Orphan+Drug+Status%2C+Furthers+Strategic+Focus+On+VT-1953+Program+Over+the+Next+6+Months/25979130.html Wed, 11 Feb 2026 07:00:00 -0500 HIND O.01228167 http://www.streetinsider.com/Business+Wire/Vyome+Files+for+VT-1953+Orphan+Drug+Status%2C+Furthers+Strategic+Focus+On+VT-1953+Program+Over+the+Next+6+Months/25979130.html <ul class="bwlistdisc"> <li> <i>Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&amp;D tax benefits, and PDUFA fee waiver of approximately $3M</i> </li> <li> <i>Independent third-party assessment estimates a current VT-1953 valuation of approximately $455M today and ~$1B after a successful Phase 3 study</i> </li> <li> <i>FDA interactions planned in Q2 2026 for the Phase 3 protocol based on earlier announced positive Phase 2 results</i> </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc. (“<b>Vyome</b>”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical http://www.streetinsider.com/Business+Wire/Vyome+Files+for+VT-1953+Orphan+Drug+Status%2C+Furthers+Strategic+Focus+On+VT-1953+Program+Over+the+Next+6+Months/25979130.html Wed, 11 Feb 2026 07:00:00 -0500 HIND O.01228167 http://www.streetinsider.com/FDA/Vyome+raises+%245.29+million+to+fund+phase+3+drug+trial/25926950.html <p>Vyome Holdings Inc. (NASDAQ: HIND) raised approximately $5.29 million through its at-the-market facility to fund its VT-1953 Phase 3 clinical study for malignant fungating wounds treatment.</p> <p>The company sold 1,089,045 common shares on January 27, 2026, at an average price of $5.00 per share, representing a 59.2% premium to the prior day's closing price of $3.11. The funding resulted in approximately 15% dilution to existing shareholders, bringing total outstanding shares to 7,008,882 as of January 29, 2026.</p> <p>Following the transaction, Vyome reported having $9.5 million in cash on hand as of January 29, 2026. The company stated the funding provides sufficient capital http://www.streetinsider.com/FDA/Vyome+raises+%245.29+million+to+fund+phase+3+drug+trial/25926950.html Mon, 02 Feb 2026 07:00:45 -0500 HIND O.01228167 http://www.streetinsider.com/FDA/Vyome+raises+%245.29+million+to+fund+phase+3+drug+trial/25926950.html <p>Vyome Holdings Inc. (NASDAQ: HIND) raised approximately $5.29 million through its at-the-market facility to fund its VT-1953 Phase 3 clinical study for malignant fungating wounds treatment.</p> <p>The company sold 1,089,045 common shares on January 27, 2026, at an average price of $5.00 per share, representing a 59.2% premium to the prior day's closing price of $3.11. The funding resulted in approximately 15% dilution to existing shareholders, bringing total outstanding shares to 7,008,882 as of January 29, 2026.</p> <p>Following the transaction, Vyome reported having $9.5 million in cash on hand as of January 29, 2026. The company stated the funding provides sufficient capital http://www.streetinsider.com/FDA/Vyome+raises+%245.29+million+to+fund+phase+3+drug+trial/25926950.html Mon, 02 Feb 2026 07:00:45 -0500 HIND O.01228167 http://www.streetinsider.com/Press+Releases/Vyome+Successfully+Capitalizes+All+VT-1953+Funding+Requirements+For+Initial+Phase+3+Results/25926932.html <p class="bwalignc"> <i>Company Chose Minimal Dilution Path with No Warrants and Has </i><i>Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Vyome Holdings, Inc. (“Vyome” or the “Company”) (Nasdaq: HIND)</b> announced it has successfully funded the budget for its VT-1953 Phase 3 study, which provides the Company sufficient capital to fund the estimated costs to release Phase 3 interim results on the efficacy of its drug focused on symptoms of Malignant Fungating Wounds (“MFW”). The Company accomplished this funding need using its existing At-The-Market (“ATM”) facility. </p><p> Additional details on this funding are as follows: </p><ul class="bwlistdisc"> <li> All http://www.streetinsider.com/Press+Releases/Vyome+Successfully+Capitalizes+All+VT-1953+Funding+Requirements+For+Initial+Phase+3+Results/25926932.html Mon, 02 Feb 2026 07:00:00 -0500 HIND O.01228167 http://www.streetinsider.com/Press+Releases/Vyome+Successfully+Capitalizes+All+VT-1953+Funding+Requirements+For+Initial+Phase+3+Results/25926932.html <p class="bwalignc"> <i>Company Chose Minimal Dilution Path with No Warrants and Has </i><i>Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Vyome Holdings, Inc. (“Vyome” or the “Company”) (Nasdaq: HIND)</b> announced it has successfully funded the budget for its VT-1953 Phase 3 study, which provides the Company sufficient capital to fund the estimated costs to release Phase 3 interim results on the efficacy of its drug focused on symptoms of Malignant Fungating Wounds (“MFW”). The Company accomplished this funding need using its existing At-The-Market (“ATM”) facility. </p><p> Additional details on this funding are as follows: </p><ul class="bwlistdisc"> <li> All http://www.streetinsider.com/Press+Releases/Vyome+Successfully+Capitalizes+All+VT-1953+Funding+Requirements+For+Initial+Phase+3+Results/25926932.html Mon, 02 Feb 2026 07:00:00 -0500 HIND O.01228167 http://www.streetinsider.com/Business+Wire/Vyome+Successfully+Capitalizes+All+VT-1953+Funding+Requirements+For+Initial+Phase+3+Results/25926932.html <p class="bwalignc"> <i>Company Chose Minimal Dilution Path with No Warrants and Has </i><i>Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Vyome Holdings, Inc. (“Vyome” or the “Company”) (Nasdaq: HIND)</b> announced it has successfully funded the budget for its VT-1953 Phase 3 study, which provides the Company sufficient capital to fund the estimated costs to release Phase 3 interim results on the efficacy of its drug focused on symptoms of Malignant Fungating Wounds (“MFW”). The Company accomplished this funding need using its existing At-The-Market (“ATM”) facility. </p><p> Additional details on this funding are as follows: </p><ul class="bwlistdisc"> <li> All http://www.streetinsider.com/Business+Wire/Vyome+Successfully+Capitalizes+All+VT-1953+Funding+Requirements+For+Initial+Phase+3+Results/25926932.html Mon, 02 Feb 2026 07:00:00 -0500 HIND O.01228167 http://www.streetinsider.com/Business+Wire/Vyome+Successfully+Capitalizes+All+VT-1953+Funding+Requirements+For+Initial+Phase+3+Results/25926932.html <p class="bwalignc"> <i>Company Chose Minimal Dilution Path with No Warrants and Has </i><i>Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product</i> </p> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- <b>Vyome Holdings, Inc. (“Vyome” or the “Company”) (Nasdaq: HIND)</b> announced it has successfully funded the budget for its VT-1953 Phase 3 study, which provides the Company sufficient capital to fund the estimated costs to release Phase 3 interim results on the efficacy of its drug focused on symptoms of Malignant Fungating Wounds (“MFW”). The Company accomplished this funding need using its existing At-The-Market (“ATM”) facility. </p><p> Additional details on this funding are as follows: </p><ul class="bwlistdisc"> <li> All http://www.streetinsider.com/Business+Wire/Vyome+Successfully+Capitalizes+All+VT-1953+Funding+Requirements+For+Initial+Phase+3+Results/25926932.html Mon, 02 Feb 2026 07:00:00 -0500 HIND O.01228167 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vyome+Holdings%2C+Inc+++++++For%3A+Jan+28/25905020.html si-local-file:///var/storage/secattach/20260128/25905020.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vyome+Holdings%2C+Inc+++++++For%3A+Jan+28/25905020.html Wed, 28 Jan 2026 09:01:00 -0500 HIND O.01228167